Insight

Meta-analysis of non-relapse mortality post-CAR-T cells in lymphoma and myeloma

Photo of David Cordas dos Santos from connects.catalyst.harvard.edu

Jul 24, 2024, 08:12

Meta-analysis of non-relapse mortality post-CAR-T cells in lymphoma and myeloma

Nature Medicine shared on X about a paper titled “A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy” published on their journal.

Authors: David M. Cordas dos Santos, Tobias Tix, Roni Shouval, Anat Gafter-Gvili, Jean-Baptiste Alberge, Edward R. Scheffer Cliff, Sebastian Theurich, Michael von Bergwelt-Baildon, Irene M. Ghobrial, Marion Subklewe, Miguel-Angel Perales and Kai Rejeski.

“In a meta-analysis of non-relapse mortality post-CAR-T cells in patients with lymphoma and myeloma, almost 1/2 of cases were caused by pathogens and mortality estimates varied across tumor types and CAR-T cell products.”

Source: Nature Medicine/X

Anat Gafter-Gvili cancer CAR T-CELL David M. Cordas dos Santos Edward R. Scheffer Cliff Irene M. Ghobrial Jean-Baptiste Alberge Kai Rejeski lymphoma Marion Subklewe Michael von Bergwelt-Baildon Miguel-Angel Perales Myeloma Nature Medicine OncoDaily Oncology Roni Shouval Sebastian Theurich Tobias Tix

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage